1414 related articles for article (PubMed ID: 17309186)
21. Tc-99m MIBI SPECT in detecting metastatic papillary thyroid carcinoma in patients with elevated human serum thyroglobulin levels but negative I-131 whole body scan.
Hsu CH; Liu FY; Yen RF; Kao CH
Endocr Res; 2003 Feb; 29(1):9-15. PubMed ID: 12665314
[TBL] [Abstract][Full Text] [Related]
22. 99mTc-sestamibi and 131I whole-body scintigraphy and initial serum thyroglobulin in the management of differentiated thyroid carcinoma.
Ng DC; Sundram FX; Sin AE
J Nucl Med; 2000 Apr; 41(4):631-5. PubMed ID: 10768563
[TBL] [Abstract][Full Text] [Related]
23. Comparison of 99mTc-methoxyisobutyl isonitrile and 201Tl scintigraphy for detection of residual thyroid cancer after 131I ablative therapy.
Seabold JE; Gurll N; Schurrer ME; Aktay R; Kirchner PT
J Nucl Med; 1999 Sep; 40(9):1434-40. PubMed ID: 10492361
[TBL] [Abstract][Full Text] [Related]
24. Clinical importance of anti-thyroglobulin auto-antibodies in patients with differentiated thyroid carcinoma: comparison with 99mTc-MIBI scans.
Küçük ON; Aras G; Kulak HA; Ibiş E
Nucl Med Commun; 2006 Nov; 27(11):873-6. PubMed ID: 17021427
[TBL] [Abstract][Full Text] [Related]
25. Comparison of FDG-PET and technetium-99m MIBI SPECT to detect metastatic cervical lymph nodes in well-differentiated thyroid carcinoma with elevated serum HTG but negative I-131 whole body scan.
Wu HS; Huang WS; Liu YC; Yen RF; Shen YY; Kao CH
Anticancer Res; 2003; 23(5b):4235-8. PubMed ID: 14666632
[TBL] [Abstract][Full Text] [Related]
26. Sensitivity of [99mTc]methoxyisobutylisonitrile scan in patients with metastatic differentiated thyroid cancer.
Ronga G; Ventroni G; Montesano T; Filesi M; Ciancamerla M; Di Nicola AD; Travascio L; Vestri AR; Signore A
Q J Nucl Med Mol Imaging; 2007 Dec; 51(4):364-71. PubMed ID: 17473819
[TBL] [Abstract][Full Text] [Related]
27. Use of
Wu D; Ylli D; Gomes Lima CJ; Lee W; Burman KD; Wartofsky L; Van Nostrand D
Endocrine; 2018 Oct; 62(1):57-63. PubMed ID: 29797211
[TBL] [Abstract][Full Text] [Related]
28. The Value of
Okudan B; Seven B; Gülaldı NCM; Çapraz M; Açıkgöz Y
Curr Med Imaging; 2022; 18(4):404-408. PubMed ID: 34749623
[TBL] [Abstract][Full Text] [Related]
29. Role of initial iodine-131 whole-body scan and serum thyroglobulin in differentiated thyroid carcinoma metastases.
Filesi M; Signore A; Ventroni G; Melacrinis FF; Ronga G
J Nucl Med; 1998 Sep; 39(9):1542-6. PubMed ID: 9744339
[TBL] [Abstract][Full Text] [Related]
30. Whole-body Tc-99m sestamibi scintigraphy in the follow-up of differentiated thyroid carcinoma.
Almeida-Filho P; Ravizzini GC; Almeida C; Borges-Neto S
Clin Nucl Med; 2000 Jun; 25(6):443-6. PubMed ID: 10836693
[TBL] [Abstract][Full Text] [Related]
31. Follow-up of differentiated thyroid cancer.
Pacini F
Eur J Nucl Med Mol Imaging; 2002 Aug; 29 Suppl 2():S492-6. PubMed ID: 12192551
[TBL] [Abstract][Full Text] [Related]
32. The predictive value of serum thyroglobulin in the follow-up of differentiated thyroid cancer.
Roelants V; Nayer PD; Bouckaert A; Beckers C
Eur J Nucl Med; 1997 Jul; 24(7):722-7. PubMed ID: 9211756
[TBL] [Abstract][Full Text] [Related]
33. Fluorodeoxyglucose PET/CT in patients with differentiated thyroid cancer and elevated thyroglobulin after total thyroidectomy and (131)I ablation.
Salvatore B; Paone G; Klain M; Storto G; Nicolai E; D'Amico D; Della Morte AM; Pace L; Salvatore M
Q J Nucl Med Mol Imaging; 2008 Mar; 52(1):2-8. PubMed ID: 17538522
[TBL] [Abstract][Full Text] [Related]
34. [99m-Tc-MIBI for recurrent and metastatic differentiated thyroid carcinoma].
Elser H; Henze M; Hermann C; Eckert W; Mende U
Nuklearmedizin; 1997 Jan; 36(1):7-12. PubMed ID: 9082340
[TBL] [Abstract][Full Text] [Related]
35. Role of [
Xu Q; Liu R; Wang J; Huang Y; Li S; Zhang L; Wang F
Nucl Med Biol; 2020; 88-89():34-43. PubMed ID: 32688289
[TBL] [Abstract][Full Text] [Related]
36. Thyroglobulin determination, neck ultrasonography and iodine-131 whole-body scintigraphy in differentiated thyroid carcinoma.
Franceschi M; Kusić Z; Franceschi D; Lukinac L; Roncević S
J Nucl Med; 1996 Mar; 37(3):446-51. PubMed ID: 8772642
[TBL] [Abstract][Full Text] [Related]
37. Thallium-201, technetium-99m-tetrofosmin and iodine-131 in detecting differentiated thyroid carcinoma metastases.
Unal S; Menda Y; Adalet I; Boztepe H; Ozbey N; Alagöl F; Cantez S
J Nucl Med; 1998 Nov; 39(11):1897-902. PubMed ID: 9829579
[TBL] [Abstract][Full Text] [Related]
38. Comparative evaluation of recombinant human thyrotropin-stimulated thyroglobulin levels, 131I whole-body scintigraphy, and neck ultrasonography in the follow-up of patients with papillary thyroid microcarcinoma who have not undergone radioiodine therapy.
Torlontano M; Crocetti U; Augello G; D'Aloiso L; Bonfitto N; Varraso A; Dicembrino F; Modoni S; Frusciante V; Di Giorgio A; Bruno R; Filetti S; Trischitta V
J Clin Endocrinol Metab; 2006 Jan; 91(1):60-3. PubMed ID: 16219716
[TBL] [Abstract][Full Text] [Related]
39. Clinical utility of technetium-99m methoxisobutylisonitrile imaging in differentiated thyroid carcinoma: comparison with thallium-201 and iodine-131 Na scintigraphy, and serum thyroglobulin quantitation.
Dadparvar S; Chevres A; Tulchinsky M; Krishna-Badrinath L; Khan AS; Slizofski WJ
Eur J Nucl Med; 1995 Nov; 22(11):1330-8. PubMed ID: 8575487
[TBL] [Abstract][Full Text] [Related]
40. Value of combined technetium-99m hydroxy methylene diphosphonate and thallium-201 imaging in detecting bone metastases from thyroid carcinoma.
Alam MS; Takeuchi R; Kasagi K; Misaki T; Miyamoto S; Iida Y; Hidaka A; Konishi J
Thyroid; 1997 Oct; 7(5):705-12. PubMed ID: 9349573
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
